Medical device startup NeuroWave Systems Inc. has reached a deal in which CareFusion (NYSE: CFN) will distribute NeuroWave’s brain-activity monitoring system in Germany and Scandinavia.
It’s an important step for Cleveland Heights, Ohio-based NeuroWave, which in June received European regulatory clearance to begin selling its NeuroSense brain monitor for assessing anesthesia levels.
The deal with CareFusion should allow NeuroWave to begin reaping the rewards of surpassing the regulatory hurdle, and being associated with a large, publicly traded company doesn’t hurt either. Cardinal Health Inc. (NYSE: CAH) spun off San Diego-based CareFusion about a year ago to focus more intensely on its supply chain business. CareFusion is a $4 billion company that makes drug-delivery systems and infection-prevention tools.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
The NeuroSense monitor acquires and displays electroencephalogram (EEG) signals from both sides of the front part of the brain. Monitoring both sides of the brain is important for detecting anesthesia-related pathologies, such as stroke, that can affect only one part of the brain.
The monitor fits well into CareFusion’s neurophysiologic and perioperative product lines, according to a statement from CareFusion.
NeuroWave was spun off in 2008 from Cleveland Medical Devices, which develops biomedical signal processing and instrumentation devices for sleep and movement disorders, like Parkinson’s.
Earlier this month, NeuroWave received U.S. regulatory clearance to begin selling a brain-monitoring system that’s similar to the NeuroSense.
